Anteris Reports Early DurAVR Heart Valve Study Results
AVR: $9.15 +3.62% · MC: $876M
Anteris Technologies Global Corp. reported no valve-related deaths or moderate or severe leaks one month after treatment in a small study of its medium-size DurAVR heart valve. The study also found no moderate or severe mismatch between the valve opening and patients’ blood-flow needs. A larger randomised trial comparing DurAVR with commercially available valves is enrolling patients.

Comments